Skip to main content

Table 7 List of countries in the Americas and their vaccine production capabilities as well as their share in the exportation market

From: Vaccine market and production capabilities in the Americas

Country Number of vaccines introduced in the EPI [74] Vaccine produced in own facility Local vaccine productiona (%) Ranking in world exports of vaccines for human use [75] bVaccine Type and target achieved [76]
Antigua and Barbuda 16 0 0 No information reported HepB3
Hib3
IPV
Pol3
DTP3
MCV2
MCV1
RCV1
99%
99%
99%
95%
95%
95%
93%
93%
Argentina 26 9 34.62 49 MCV1
RCV1
BCG
IPV
MCV2
PCV3
HepB3
Hib3
DTP3
Pol3
RV
YFV
94%
94%
93%
90%
89%
88%
86%
86%
86%
84%
72%
8%
Bahamas 22 0 0 No information reported IPV
Hep3
Hib3
PCV3
Pol3
DTP3
MCV1
RCV1
MCV2
RV
91%
86%
86%
86%
86%
86%
86%
85%
82%
78%
Barbados 15 0 0 63 IPV
PCV3
MCV1
RCV1
Pol3
HepB3
Hib3
DTP3
MCV
94%
93%
92%
92%
91%
90%
90%
90%
77%
Belize 16 0 0 No information reported IPV
Hib3
Pol3
DTP3
MCV1
RCV1
BCG
MCV2
HepB3
99%
98%
98%
98%
96%
96%
95%
95%
98%
Bolivia 14 1 7.14 No information reported IPV
BCG
MCV1
RCV1
RV
YFV
HepB3
Hib3
PCV3
Pol3
DTP
MCV2
81%
80%
79%
78%
77%
75%
75%
75%
75%
75%
75%
44%
Brazil 27 13 48.15 32 MCV1
RCV1
IPV
Poli3
PCV3
RV
HepB3
Hib3
BCG
DTP3
YFV
MCV2
91%
91%
86%
85%
84%
83%
80%
80%
79%
73%
60%
54%
Canada 21 5 23.81 11 IPV
Hib3
Pol3
DTP3
MCV1
RCV1
MCV2
PCV3
RV
HepB3
94%
91%
91%
91%
90%
90%
87%
81%
79%
74%
Chile 19 0 0 No information reported IPV
BCG
HepB3
Hib3
Pol3
DTP3
MCV1
PCV3
RCV1
MCV2
99%
98%
96%
96%
96%
96%
95%
95%
95%
91%
Colombia 22 3 13.64 54 MCV1
RCV1
PCV3
IPV
HepB3
Hib3
Pol3
DTP3
RV
BCG
MCV2
YFV
95%
95%
94%
93%
92%
92%
92%
92%
90%
89%
88%
87%
Costa Rica 15 0 0 74 HepB3
IPV
MCV1
PCV3
RCV1
DTP3
Hib3
Pol3
MCV2
BCG
RV
98%
96%
95%
95%
95%
95%
94%
94%
93%
88%
59%
Cuba 16 9 56.25% 43 BCG
HepB3
Hib3
IPV
MCV1
Pol3
RCV1
DTP3
MCV2
99%
99%
99%
99%
99%
99%
99%
99%
99%
Dominica 14 0 0 No information reported HepB3
Hib3
IPV
Pol3
DTP
BCG
MCV1
RCV1
MCV2
99%
99%
99%
99%
99%
98%
92%
92%
92%
Dominican Republic 18 0 0 No information reported BCG
IPV
MCV1
RCV1
Pol3
DTP3
HepB3
RV
Hib3
PCV3
MCV2
99%
98%
96%
96%
92%
89%
87%
80%
79%
70%
60%
Ecuador 18 2 11.1 No information reported BCG
HepB3
Hib3
IPV
Pol3
RV
DTP3
YFV
MCV1
PCV3
RCV1
MCV2
86%
85%
85%
85%
85%
85%
85%
84%
83%
83%
83%
76%
El Salvador 19 0 0 No information reported IPV
Hib3
Pol3
DTP3
MCV1
RCV1
MCV2
BCG
HepB3
PCV3
RV
81%
81%
81%
81%
82%
82%
87%
78%
81%
82%
82%
Grenada 14 0 0 No information reported IPV
HepB3
Hib3
MCV1
Pol3
RCV1
DTP3
MCV2
96%
94%
94%
94%
94%
94%
92%
82%
Guatemala 18 0 0 No information reported IPV
Hib3
Pol3
DTP3
MCV1
RCV1
MCV2
PCV3
RV
HepB3
90%
86%
79%
85%
90%
90%
78%
88%
86%
86%
Guyana 16 0 0 81 BCG
HepB3
Hib3
IPV
RV
DTP3
MCV1
PCV3
RCV1
Pol3
YFV
MCV2
99%
99%
99%
99%
99%
99%
98%
98%
98%
97%
94%
92%
Haiti 9 0 0 No information reported IPV
Pol3
BCG
MCV1
RCV1
HepB3
Hib3
DTP3
RV
PVC3
MCV2
78%
74%
73%
65%
65%
51%
51%
51%
48%
42%
41%
Honduras 20 0 0 No information reported IPV
BCG
RV
HepB3
Hib3
MCV1
PCV3
Pol3
RCV1
DTP3
MCV2
90%
88%
88%
87%
87%
87%
87%
87%
87%
87%
85%
Jamaica 16 0 0 No information reported BCG
IPV
HepB3
Pol3
DTP3
Mcv1
RCV1
MCV2
97%
97%
96%
96%
96%
94%
94%
92%
Mexico 20 7 35 35 IPV
Hib3
Pol3
DTP3
MCV1
RCV1
MCV2
PCV3
RV
HepB3
84%
82%
82%
82%
73%
73%
73%
86%
82%
56%
Nicaragua 15 4 26.67 31 IPV
MCV1
Pol3
RCV1
MCV2
BCG
HepB3
Hib3
PCV3
RV
DTP3
99%
99%
99%
99%
99%
98%
98%
98%
98%
98%
98%
Panama 25 1 4 34 BCG
MCV1
RCV1
MCV2
IPV
PCV3
RV
HepB3
Hib3
Pol3
DTP3
YFV
99%
97%
97%
97%
96%
96%
94%
88%
88%
88%
88%
7%
Paraguay 26 0 0 No information reported YFV
PCV3
IPV
BCG
MCV1
RCV1
HepB3
Hib3
RV
DTP
Pol3
MCV2
92%
89%
88%
87%
87%
87%
86%
86%
86%
86%
84%
83%
Peru 20 0 0 No information reported RV
IPV
HepB3
Hib3
DTP
Pol3
MCV1
RCV1
BCG
PCV3
MCV2
YFV
90%
89%
88%
88%
88%
87%
85%
85%
81%
80%
66%
57%
Saint Kitts and Nevis 13 0 0 No information reported BCG
MCV2
HepB3
Hib3
IPV
MCV1
RCV1
Pol3
DTP3
99%
98%
97%
97%
97%
97%
97%
96%
96%
Saint Vincent and the Grenadines 13 0 0 No information reported BCG
MCV1
Pol3
RCV1
MCV2
HepB3
Hib3
DTP3
IPV
99%
99%
99%
99%
99%
97%
97%
97%
96%
Suriname 17 0 0 No information reported IPV
HepB3
Hib3
DTP3
Pol3
MCV1
RCV1
MCV2
YFV
82%
77%
77%
77%
76%
64%
64%
58%
57%
Trinidad and Tobago 16 0 0 83 MCV1
RCV1
YFV
HepB3
Hib3
PCV3
Pol3
DTP3
IPV
MCV2
99%
99%
98%
93%
93%
93%
93%
93%
92%
92%
United States 30 18 60 5 IPV
Hib3
Pol3
DTP3
MCV1
RCV1
MCV2
PCV3
RV
HepB3
97%
91%
93%
94%
90%
90%
95%
92%
74%
91%
Uruguay 19 2 10.53 No information reported BCG
IPV
MCV2
MCV1
RCV1
PCV3
HepB3
Hib3
DTP3
Pol3
99%
99%
99%
96%
96%
95%
94%
94%
94%
93%
Venezuela 16 4 25 No information reported MCV1
RCV1
BCG
YFV
HepB3
Hib3
DTP3
Poli3
IPV
MCV2
93%
93%
91%
80%
64%
64%
64%
62%
55%
13%
  1. aThe percentage of self-sufficiency in vaccine production is estimated as the number of different types of vaccines produced by national manufacturers as a function of the number of vaccines in use by the immunization program
  2. bBCG bacille Calmette–Guerin, HepB hepatitis B virus, DTP diphtheria, tetanus, and pertussis, MMR mumps, measles, and rubella, Hib Haemophilus influenzae type B, HPV human papillomavirus, MCV vaccine meningococcal conjugate vaccine, DPT diphtheria-tetanus-pertussis